We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

59 hedge funds and large institutions have $138M invested in Orchestra BioMed in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

11% more funds holding

Funds holding: 53 → 59 (+6)

7% more capital invested

Capital invested by funds: $129M → $138M (+$8.57M)

6.04% more ownership

Funds ownership: 62.75% → 68.8% (+6%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
59
Holders Change
+6
Holders Change %
+11.32%
% of All Funds
0.93%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
14
Increased
10
Reduced
6
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
+$7.28M
2
SC
Sculptor Capital
New York
+$4.85M
3
RCM
Radcliffe Capital Management
Pennsylvania
+$4.02M
4
CC
Centiva Capital
New York
+$3.31M
5
WRBC
W.R. Berkley Corp
Connecticut
+$1.98M

Top Sellers

Rank Fund Capital Flow
1
PI
Putnam Investments
Massachusetts
-$7.5M
2
O
OrbiMed
New York
-$5.04M
3
KPF
K2 Principal Fund
Ontario, Canada
-$4.29M
4
M
Murchinson
Ontario, Canada
-$1.97M
5
Wellington Management Group
Wellington Management Group
Massachusetts
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of Montreal
26
Bank of Montreal
Ontario, Canada
$1.99M +$494K +50,000 +33%
SCM
27
Shaolin Capital Management
Florida
$1.98M +$1.48M +150,000 +300%
KIM
28
Karpus Investment Management
New York
$1.6M +$1.59M +161,000 New
LP
29
LMR Partners
United Kingdom
$1.44M +$1.43M +145,108 New
LSC
30
Logan Stone Capital
Illinois
$1.27M +$1.26M +127,730 New
PVI
31
Pura Vida Investments
New York
$1.03M +$4.94K +500 +0.5%
M
32
Murchinson
Ontario, Canada
$992K -$1.97M -199,885 -67%
CIM
33
Cowen Investment Management
New York
$991K +$988K +100,000 New
Marshall Wace
34
Marshall Wace
United Kingdom
$798K – – –
PMAM
35
Picton Mahoney Asset Management
Ontario, Canada
$778K – – –
HI
36
HBK Investments
Texas
$610K – – –
Millennium Management
37
Millennium Management
New York
$591K -$596K -60,371 -50%
Goldman Sachs
38
Goldman Sachs
New York
$578K +$576K +58,336 New
HF
39
HRT Financial
New York
$495K +$337K +34,149 +216%
SCC
40
Spring Creek Capital
Kansas
$460K +$458K +46,394 New
TD Asset Management
41
TD Asset Management
Ontario, Canada
$459K – – –
AI
42
Arena Investors
New York
$431K +$430K +43,526 New
MF
43
Magnetar Financial
Illinois
$409K – – –
Alyeska Investment Group
44
Alyeska Investment Group
Illinois
$248K – – –
Nomura Holdings
45
Nomura Holdings
Japan
$204K – – –
CCM
46
CAAS Capital Management
New York
$201K +$201K +20,300 New
SC
47
Sagefield Capital
Texas
$181K – – –
DFCM
48
Dark Forest Capital Management
Puerto Rico
$172K -$366K -37,044 -68%
Geode Capital Management
49
Geode Capital Management
Massachusetts
$123K – – –
6CM
50
683 Capital Management
New York
$99K – – –
1
2
3

OBIO Hedge Fund Activity: Q1 2022 in Review

59 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q1 2022, worth a combined $138M — up 6.6% from $129M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new OBIO positions and 8 closed out — a net gain of 6 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was Saba Capital Management, opening a new position worth an estimated $7.28M. The largest seller was Putnam Investments, exiting entirely with an estimated $7.5M sold.

  • 59 institutional investors held Orchestra BioMed (OBIO) as of Q1 2022, up from 53 in Q4 2021.
  • Funds reported $138M of Orchestra BioMed stock for Q1 2022, up 6.6% quarter-over-quarter.
  • 14 funds opened new Orchestra BioMed positions in Q1 2022 and 8 closed out, a net change of +6 holders.
  • The largest Orchestra BioMed buyer in Q1 2022 was Saba Capital Management, an estimated $7.28M added.
  • The largest Orchestra BioMed seller in Q1 2022 was Putnam Investments, an estimated $7.5M sold.

Based on aggregated 13F filings for Q1 2022.